CLDN 18.2-positive metastatic HER2 negative Gastroesophageal Junction Adenocarcinoma
CLDN 18.2-positive metastatic HER2 negative Gastroesophageal Junction Adenocarcinoma is the indication for 1 drug in DrugBank. It is covered by 1 curated, structured indication.
- Classified under
- Indicated drugs
What you can answer from here — as of October 25, 2026
1Indicated drugWith each drug's targets and mechanismListed above
1Structured indicationPopulation, line of therapy, route and combination as fields, not proseSign in
Which approved drugs for CLDN 18.2-positive metastatic HER2 negative Gastroesophageal Junction Adenocarcinoma share a target, and which companies have late-stage candidates against it?
Create a free account or log in to explore the full data card.
Create Account